BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23418310)

  • 1. Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis.
    Comino-Méndez I; de Cubas AA; Bernal C; Álvarez-Escolá C; Sánchez-Malo C; Ramírez-Tortosa CL; Pedrinaci S; Rapizzi E; Ercolino T; Bernini G; Bacca A; Letón R; Pita G; Alonso MR; Leandro-García LJ; Gómez-Graña A; Inglada-Pérez L; Mancikova V; Rodríguez-Antona C; Mannelli M; Robledo M; Cascón A
    Hum Mol Genet; 2013 Jun; 22(11):2169-76. PubMed ID: 23418310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-Inducible Factor 2α Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster.
    Fliedner SM; Shankavaram U; Marzouca G; Elkahloun A; Jochmanova I; Daerr R; Linehan WM; Timmers H; Tischler AS; Papaspyrou K; Brieger J; de Krijger R; Breza J; Eisenhofer G; Zhuang Z; Lehnert H; Pacak K
    Neoplasia; 2016 Sep; 18(9):567-76. PubMed ID: 27659016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma.
    Lorenzo FR; Yang C; Ng Tang Fui M; Vankayalapati H; Zhuang Z; Huynh T; Grossmann M; Pacak K; Prchal JT
    J Mol Med (Berl); 2013 Apr; 91(4):507-12. PubMed ID: 23090011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
    Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
    Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas.
    López-Jiménez E; Gómez-López G; Leandro-García LJ; Muñoz I; Schiavi F; Montero-Conde C; de Cubas AA; Ramires R; Landa I; Leskelä S; Maliszewska A; Inglada-Pérez L; de la Vega L; Rodríguez-Antona C; Letón R; Bernal C; de Campos JM; Diez-Tascón C; Fraga MF; Boullosa C; Pisano DG; Opocher G; Robledo M; Cascón A
    Mol Endocrinol; 2010 Dec; 24(12):2382-91. PubMed ID: 20980436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HIF-1alpha, HIF-2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations.
    Pollard PJ; El-Bahrawy M; Poulsom R; Elia G; Killick P; Kelly G; Hunt T; Jeffery R; Seedhar P; Barwell J; Latif F; Gleeson MJ; Hodgson SV; Stamp GW; Tomlinson IP; Maher ER
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4593-8. PubMed ID: 16954163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas.
    Amorim-Pires D; Peixoto J; Lima J
    Cytogenet Genome Res; 2016; 150(3-4):227-241. PubMed ID: 28231563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
    Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
    J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
    Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
    Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
    Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
    Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.
    Taïeb D; Yang C; Delenne B; Zhuang Z; Barlier A; Sebag F; Pacak K
    J Clin Endocrinol Metab; 2013 May; 98(5):E908-13. PubMed ID: 23539726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATRX driver mutation in a composite malignant pheochromocytoma.
    Comino-Méndez I; Tejera ÁM; Currás-Freixes M; Remacha L; Gonzalvo P; Tonda R; Letón R; Blasco MA; Robledo M; Cascón A
    Cancer Genet; 2016 Jun; 209(6):272-7. PubMed ID: 27209355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
    Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
    Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
    Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genomic landscape of phaeochromocytoma.
    Flynn A; Benn D; Clifton-Bligh R; Robinson B; Trainer AH; James P; Hogg A; Waldeck K; George J; Li J; Fox SB; Gill AJ; McArthur G; Hicks RJ; Tothill RW
    J Pathol; 2015 May; 236(1):78-89. PubMed ID: 25545346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.
    Pang Y; Gupta G; Jha A; Yue X; Wang H; Huynh TT; Li A; Li L; Baker E; Chew E; Feelders RA; Korpershoek E; Zhuang Z; Yang C; Pacak K
    Cancer; 2019 Apr; 125(8):1258-1266. PubMed ID: 30644531
    [TBL] [